-transparent.png){kind=logo}
Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone; dihydroxyanthracenedione) was administered in a dose of 8-13 mg/m2 on five consecutive days. Five of 20 evaluable patients were induced into complete remission, one patient achieved a partial remission. Side-effects included moderate to severe bone marrow suppression, moderate mucositis and hair loss. No cardiotoxicity was observed. We believe that mitoxantrone is an active agent in the treatment of acute leukemia and suggest further studies in combination chemotherapy.
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
September 1984,
Seminars in oncology,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
September 1984,
Seminars in oncology,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
August 1990,
Cancer,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
January 1988,
Medical and pediatric oncology,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
January 1989,
Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
July 1994,
Nouvelle revue francaise d'hematologie,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
January 1990,
Haematology and blood transfusion,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
January 1990,
Nouvelle revue francaise d'hematologie,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
March 2001,
Zhongguo shi yan xue ye xue za zhi,
P Meyer, and
A D Ho, and
G Ehninger, and
I Mjaaland, and
E Heidemann, and
E Seither
May 1992,
Gan to kagaku ryoho. Cancer & chemotherapy,
